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CONCLUSIONS: Schizophrenia patients consume signif-
icant health care resources. Medications used to treat
schizophrenia did not differ in terms of duration of ther-
apy or impact on total health care costs.
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Hospitals, health care systems, and policy makers are
striving to seek ways to provide cost-effective care for pa-
tients with major depressive disorder.
OBJECTIVES: The first objective is to investigate the dif-
ferences between the newer antidepressants regarding
treatment completion, average daily dose, dosage titration,
switching, and augmentation behavior. The second objec-
tive is to compare direct health service expenditures related
to the treatment of depression. The inquiry is guided by the
following question: Is there a significant difference be-
tween antidepressants in regard to overall health care ser-
vice expenditures for the treatment of depression?
METHODS: Retrospective archival data from computer-
ized claims records of a large managed care organization
were analyzed. Treatment completion was defined as re-
ceiving at least 180 days of therapy at a minimum thera-
peutic dose as defined by the AHCPR guidelines for de-
tection, diagnosis, and treatment of depression. Patients
were included in the analysis if (1) they had an ICD-9 di-
agnosis code for depression or if (2) they received an anti-
depressant prescription. Patients were excluded if (1) they
were less than 18 years of age, (2) they had a diagnosis
indicating schizophrenia or bipolar depression, (3) there
were not at least 6 months of follow up data available, or
(4) they were ineligible for coverage by the plan.
RESULTS: Patients initiated on fluoxetine were more
likely to complete therapy than those on paroxetine, ser-
traline, nefazodone, or venlafaxine (n = 65,792; p <
.01). These differences narrowed over time. Results re-
garding overall health care utilization related to each an-
tidepressant will be presented.
CONCLUSIONS: Based on this sample of patients, it ap-
pears that patients initiated on fluoxetine are more likely
to complete therapy when compared to the other anti-
depressants.
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Abstracts
While sedative-hypnotic agents may be equally effective
in promoting sleep, some may lead to greater impairment
in psychomotor functioning and an increased risk of mo-
tor vehicle accidents (MYAs).
OBJECTIVE: To create a general model of the impact of
alternative sedative-hypnotic agents on the expected num-
bers and associated costs of MYAs.
METHODS: A decision-analytic model was developed to
compare the effects of alternative sedative-hypnotics over
one month in a hypothetical cohort of 100,000 adult
drivers who were not being treated with these agents.
Since insomnia increases the risk of driving drowsy, pos-
sibly leading to additional MYAs, a scenario of no treat-
ment was included for comparison purposes. Outcomes
included the expected numbers of drowsy drivers and
MYAs, and the costs (societal) associated with MYAs.
Model parameters were estimated using published sur-
veys, randomized clinical trials of driving performance,
and epidemiologic studies relating driving impairment to
the risk of MYAs.
RESULTS: If sedative-hypnotics were not used, there
would be 24,300 drowsy drivers (per 100,000 per
month) and 441 MYAs. Monthly accident costs would be
$36 per person. Treatment with a sedative-hypnotic asso-
ciated with limited impairment (e.g., nitrazepam 5 mg
daily) would reduce the number of drowsy drivers to
17,550 but only slightly reduce MYAs (by 2) and
monthly costs (by less than $1 per patient). A medication
that might severely impair driving (e.g., flurazepam 30
mg daily) would not further reduce the number of drowsy
drivers but more than triple MYAs (to 1,488) and
monthly costs (to $122 per person).
CONCLUSIONS: Some sedative-hypnotic agents may
markedly increase the costs of MYAs. Their acquisition
prices alone therefore may provide a poor indication of
overall economic impact.
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Long periods of antipsychotic pharmacotherapy are often
necessary because many of the psychotic conditions indi-
cated for antipsychotics are chronic in nature. Atypical
antipsychotic agents, with a broader response profile and
fewer side effects, may increase the likelihood of achiev-
ing longer periods of pharmacotherapy relative to typical
antipsychotic agents.
OBJECTIVE: This study compares the duration of con-
tinuous therapy between atypical and typical antipsy-
chotics in the naturalistic care setting.
METHODS: Three years of medical claims data from a
large U.S. prescription database were analyzed for 56,682
